We are operating with a skeleton staff rota system for the safety and well-being of our colleagues, families and the wider community on the advice of the UK Government COVID-19 pandemic restrictions as of 24th March 2020.
Some team members will only be working remotely. As a result of these measures we may not be able to respond to your email as quickly as we would like to, but we will respond as soon as we can. We very much appreciate your understanding.
High Quality | Rapid | Scalable | Competitive
It is our goal at Leaf Expression Systems to help improve lives by accelerating research and lowering costs in the development and manufacture of therapeutic drugs, vaccines and diagnostics. Our plant-based expression technology delivers rapid, scalable, production of quality products that are competitive to produce.
We believe that unlike more established processes, our technology can deliver drugs more quickly and more cost effectively, therefore reducing the time from clinic to market. Not only does this help to reduce the time it takes to get new drugs to patients and at a cheaper cost, it also adds the possibility of extension onto patent life.
Plant-based expression systems have significant technical advantages. It is these advantages that enable us to deliver the rapid and scalable production of high quality products.
Originally developed at the world renowned John Innes Centre in Norwich, the Hypertrans® system is the core technology we use. The system allows for the simultaneous production of multiple gene products in a controlled and coordinated manner within the tissues of plants.
We produce proteins, including antibodies and allergens, enzymes and vaccines.
All of our products are of the highest quality and made without using animal derivatives, therefore eliminating the risk of any animal derived infectious material being processed within the new drugs.
Our products are produced at our state-of-the art facility by Agrobacterium-Mediated transient expression in Nicotiana benthamiana and are all designed and engineered to appropriate containment and safety standards.
Companies work with us to develop and scale the production of their products and intermediates. We also work with academic scientists, including grant funded projects to translate their science into scalable processes or to develop new enabling technologies.
We are a Contract Development and Manufacturing Organisation (CDMO) specialising in plant-based expression and the production of proteins, vaccines and complex natural products for research and commercial applications.
The company is based in a purpose-built, state-of-the-art facility on the Norwich Research Park. Our facility has environmentally controlled growing rooms supported by plant potting areas, a plant inoculation area, microbiology/molecular biology labs, protein purification and natural product processing facilities.
The quality of our products and services are without doubt key to our success, this however is only possible by having a highly specialised team in place.
Our team are the bricks and mortar of our business and are what drive us forward. Our scientific team are all experts in plant-based expression, with backgrounds in pharma, academia, biotech, commercial science and international life science industries.
Plant-based expression systems have a range of technical advantages. These include; insertion gene size, yield, propagation, protein assembly and folding accuracy, product quality and homogeneity, distribution and storage temperature, together with scale-up, speed and flexibility this leads to significant reductions in manufacturing costs of goods and above all, costs to patients.
The Hypertrans® system allows for the rapid simultaneous production of multiple gene products in a controlled and coordinated manner within the tissues of plants. Using gene synthesis and modular vectors, new products such as vaccines, antibodies or enzymes can be rapidly produced on a large scale making it well suited to be able to rapidly respond to emergencies like pandemics.